Results
|
|
1.
|
Higher burden of cardiometabolic and socioeconomic risk factors in women with type 2 diabetes: an analysis of the Glycemic Reduction Approaches in Diabetes (GRADE) baseline cohort. MedStar authors:
Year: 2023
Citation: - BMJ Open Diabetes Research & Care. 11(2), 2023 04.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - AbouAssi H, Ahmann AJ, Aroda VR, Butera NM, Desouza C, Green JB, Gulanski BI, Harindhanavudhi T, Krause-Steinrauf H, Lichtman JH, Suratt CE, Wexler DJ
|
|
|
2.
|
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. MedStar authors:
Year: 2017
Citation: - Diabetes, Obesity & Metabolism. 19(10):1408-1415, 2017 Oct.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bergenstal RM, Bonadonna RC, Kapitza C, LixiLan-L trial investigators, Niemoeller E, Puig-Domingo M, Souhami E, Stager W, Wysham C, Yu C
|
|
|
3.
|
Steroid Sex Hormones, Sex Hormone-Binding Globulin, and Diabetes Incidence in the Diabetes Prevention Program. MedStar authors:
Year: 2015
Citation: - Journal of Clinical Endocrinology & Metabolism. 100(10):3778-86, 2015 Oct.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, P.H.S.
All authors: - Aroda VR, Barrett-Connor E, Christophi CA, Diabetes Prevention Program, Edelstein SE, Florez JC, Goldberg RB, Kahn SE, Kim C, Knowler WC, Labrie F, Mather KJ
|
|
|
4.
|
The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. MedStar authors:
- Aroda, Vanita R
- Ratner, Robert E
Year: 2015
Citation: - Journal of Clinical Endocrinology & Metabolism. 100(4):1646-53, 2015 Apr.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Observational Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
All authors: - Ackermann RT, Aroda VR, Barrett-Connor E, Christophi CA, Delahanty LM, Diabetes Prevention Program Research Group, Edelstein SL, Herman WH, Knowler WC, Montez MG, Ratner RE, Zhang P, Zhuo X
|
|
|
5.
|
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). MedStar authors:
Year: 2017
Citation: - Diabetic Medicine. 34(12):1747-1755, 2017 Dec.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Barrett-Connor E, Dabelea D, Dagogo-Jack S, Hamman RF, Kahn SE, Knowler WC, Mather KJ, Pan Q, Perreault L, The Diabetes Prevention Program Research Group
|
|
|
6.
|
Neuropsychiatric safety with liraglutide 3.0mg for weight management: results from randomized controlled phase 2 and 3a trials. MedStar authors:
Year: 2017
Citation: - Diabetes, Obesity & Metabolism. 19(11):1529-1536, 2017 Nov.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Astrup A, Brett J, Cancino A, Kushner R, Lau DC, O'Neil PM, Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups, Wadden TA, Wilding JP
|
